189 related articles for article (PubMed ID: 18493149)
1. Patients with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency can achieve their target height: the Leipzig experience.
Hoepffner W; Kaufhold A; Willgerodt H; Keller E
Horm Res; 2008; 70(1):42-50. PubMed ID: 18493149
[TBL] [Abstract][Full Text] [Related]
2. [Comparative study of prednisolone versus hydrocortisone acetate for treatment of patients with the classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency].
Leite FM; Longui CA; Kochi C; Faria CD; Borghi M; Calliari LE; Monte O
Arq Bras Endocrinol Metabol; 2008 Feb; 52(1):101-8. PubMed ID: 18345402
[TBL] [Abstract][Full Text] [Related]
3. Sodium Chloride Supplementation Is Not Routinely Performed in the Majority of German and Austrian Infants with Classic Salt-Wasting Congenital Adrenal Hyperplasia and Has No Effect on Linear Growth and Hydrocortisone or Fludrocortisone Dose.
Bonfig W; Roehl F; Riedl S; Brämswig J; Richter-Unruh A; Fricke-Otto S; Hübner A; Bettendorf M; Schönau E; Dörr H; Holl RW; Mohnike K
Horm Res Paediatr; 2018; 89(1):7-12. PubMed ID: 29073619
[TBL] [Abstract][Full Text] [Related]
4. Obesity among children and adolescents with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
Völkl TM; Simm D; Beier C; Dörr HG
Pediatrics; 2006 Jan; 117(1):e98-105. PubMed ID: 16396852
[TBL] [Abstract][Full Text] [Related]
5. Final height of patients with classical congenital adrenal hyperplasia.
Aycan Z; Akbuğa S; Cetinkaya E; Ocal G; Berberoğlu M; Evliyaoğlu O; Adiyaman P
Turk J Pediatr; 2009; 51(6):539-44. PubMed ID: 20196386
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal analysis of growth and puberty in 21-hydroxylase deficiency patients.
Van der Kamp HJ; Otten BJ; Buitenweg N; De Muinck Keizer-Schrama SM; Oostdijk W; Jansen M; Delemarre-de Waal HA; Vulsma T; Wit JM
Arch Dis Child; 2002 Aug; 87(2):139-44. PubMed ID: 12138066
[TBL] [Abstract][Full Text] [Related]
7. Reduced final height outcome in congenital adrenal hyperplasia under prednisone treatment: deceleration of growth velocity during puberty.
Bonfig W; Bechtold S; Schmidt H; Knorr D; Schwarz HP
J Clin Endocrinol Metab; 2007 May; 92(5):1635-9. PubMed ID: 17299071
[TBL] [Abstract][Full Text] [Related]
8. Experience with long-term glucocorticoid treatment in congenital adrenal hyperplasia: growth pattern compared with genetic height potential.
Aycan Z; Ocal G; Berberoglu M; Cetinkaya E; Adiyaman P; Evliyaoglu O
J Pediatr Endocrinol Metab; 2006 Mar; 19(3):245-51. PubMed ID: 16607925
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up of children with classic congenital adrenal hyperplasia: suggestions for age dependent treatment in childhood and puberty.
Pijnenburg-Kleizen KJ; Thomas CMG; Otten BJ; Roeleveld N; Claahsen-van der Grinten HL
J Pediatr Endocrinol Metab; 2019 Oct; 32(10):1055-1063. PubMed ID: 31573958
[TBL] [Abstract][Full Text] [Related]
10. Growth pattern of untreated boys with simple virilizing congenital adrenal hyperplasia indicates relative androgen insensitivity during the first six months of life.
Bonfig W; Schwarz HP
Horm Res Paediatr; 2011; 75(4):264-8. PubMed ID: 21196707
[TBL] [Abstract][Full Text] [Related]
11. Treatment and disease effects on short-term growth and adult height in children and adolescents with 21-hydroxylase deficiency.
Hauffa BP; Winter A; Stolecke H
Klin Padiatr; 1997; 209(2):71-7. PubMed ID: 9113619
[TBL] [Abstract][Full Text] [Related]
12. Early growth, pubertal development, body mass index and final height of patients with congenital adrenal hyperplasia: factors influencing the outcome.
Manoli I; Kanaka-Gantenbein Ch; Voutetakis A; Maniati-Christidi M; Dacou-Voutetakis C
Clin Endocrinol (Oxf); 2002 Nov; 57(5):669-76. PubMed ID: 12390343
[TBL] [Abstract][Full Text] [Related]
13. Blood pressure in children and adolescents with congenital adrenal hyperplasia (21-hydroxylase deficiency): a preliminary report.
Roche EF; Charmandari E; Dattani MT; Hindmarsh PC
Clin Endocrinol (Oxf); 2003 May; 58(5):589-96. PubMed ID: 12699440
[TBL] [Abstract][Full Text] [Related]
14. Growth pattern during the first 36 months of life in congenital adrenal hyperplasia (21-hydroxylase deficiency).
Gasparini N; Di Maio S; Salerno M; Argenziano A; Franzese A; Tenore A
Horm Res; 1997; 47(1):17-22. PubMed ID: 9010713
[TBL] [Abstract][Full Text] [Related]
15. HYDROCORTISONE THERAPY AND GROWTH TRAJECTORY IN CHILDREN WITH CLASSICAL CONGENITAL ADRENAL HYPERPLASIA.
Bizzarri C; Improda N; Maggioli C; Capalbo D; Roma S; Porzio O; Salerno M; Cappa M
Endocr Pract; 2017 May; 23(5):546-556. PubMed ID: 28225306
[TBL] [Abstract][Full Text] [Related]
16. Adult height of subjects with nonclassical 21-hydroxylase deficiency.
Eyal O; Tenenbaum-Rakover Y; Shalitin S; Israel S; Weintrob N
Acta Paediatr; 2013 Apr; 102(4):419-23. PubMed ID: 23298233
[TBL] [Abstract][Full Text] [Related]
17. Adult height in women with early-treated congenital adrenal hyperplasia (21-hydroxylase type): relation to body mass index in earlier childhood.
Yu AC; Grant DB
Acta Paediatr; 1995 Aug; 84(8):899-903. PubMed ID: 7488814
[TBL] [Abstract][Full Text] [Related]
18. Near-final height in 82 Chinese patients with congenital adrenal hyperplasia due to classic 21-hydroxylase deficiency: a single-center study from China.
Juan L; Huamei M; Zhe S; Yanhong L; Hongshan C; Qiuli C; Jun Z; Song G; Minlian D
J Pediatr Endocrinol Metab; 2016 Jul; 29(7):841-8. PubMed ID: 27054598
[TBL] [Abstract][Full Text] [Related]
19. Impact of availability of oral hydrocortisone on growth of children with CAH.
Khadilkar VV; Khadilkar AV; Maskati GB
Indian J Pediatr; 2005 Apr; 72(4):301-3. PubMed ID: 15876756
[TBL] [Abstract][Full Text] [Related]
20. Growth patterns in the first three years of life in children with classical congenital adrenal hyperplasia diagnosed by newborn screening and treated with low doses of hydrocortisone.
Bonfig W; Schmidt H; Schwarz HP
Horm Res Paediatr; 2011; 75(1):32-7. PubMed ID: 20714115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
